Ftse Mib
34.436,59
-1,12%
DAX
18.677,11
-0,48%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
71.094,84
-0,50%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ DMK Pharmaceuticals Corporation (DMK) DMK Pharmaceuticals Corporation (DMK) Notizie

DMK Pharmaceuticals Corporation

DMK
0,232
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 02:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
21/3/202419:23EDGAR2Form 25-NSE - Notification filed by national security..
07/2/202423:19EDGAR2Form 8-K - Current report
06/2/202416:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202415:00EDGAR2Form 8-K - Current report
31/1/202423:17EDGAR2Form 8-K - Current report
23/1/202423:23EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/1/202423:22EDGAR2Form 8-K - Current report
03/1/202423:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03/1/202423:02EDGAR2Form 8-K - Current report
03/1/202423:00EDGAR2Form 8-K - Current report
21/12/202318:31EDGAR2Form 8-K - Current report
21/12/202314:15GLOBEDMK Pharmaceuticals Regains Full Rights to Commercialize..
04/12/202322:47EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/12/202322:45EDGAR2Form 8-K - Current report
28/11/202322:41EDGAR2Form 8-K - Current report
28/11/202314:05GLOBEDMK Pharmaceuticals Regains Full Rights from US WorldMeds..
15/11/202322:39EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/11/202322:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/11/202322:11EDGAR2Form 8-K - Current report
15/11/202322:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
14/11/202321:57EDGAR2Form 8-K - Current report
14/11/202313:30GLOBEDMK Pharmaceuticals Reports Third Quarter 2023 Financial..
13/11/202316:52GLOBEDMK Pharmaceuticals Announces Presentation of Preclinical..
02/11/202321:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:31EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/10/202312:30GLOBEDMK Pharmaceuticals Announces Inducement Option Grant Under..
25/10/202323:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/10/202323:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/10/202322:15GLOBEDMK Pharmaceuticals Announces Inducement Option Grant Under..
19/10/202323:07EDGAR2Form 8-K - Current report
19/10/202322:05GLOBEDMK Pharmaceuticals Restructures Executive Team to Support..
17/10/202322:37EDGAR2Form 8-K - Current report
17/10/202318:28EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
12/10/202322:22EDGAR2Form DEFC14A - Definitive proxy statement, contested..
10/10/202312:01EDGAR2Form 8-K - Current report
02/10/202322:49EDGAR2Form PREC14A - Preliminary proxy statements, contested..
26/9/202314:37EDGAR2Form SC 13D/A - General statement of acquisition of..
19/9/202323:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202318:00GLOBEAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals..
Apertura: Min: Max:
Chiusura: 0,232

La tua Cronologia

NASDAQ
DMK
DMK Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network